ATS meeting 2021 addresses health disparities in respiratory disease
Conducted June 2021 by Dr Susanne KammererProf. Juan C. Celedón is Immediate Past President of the American Thoracic Society (ATS) and the Niels K. Jerne Professor of Paediatrics and Professor of Medicine, Epidemiology, and Human Genetics at the University of Pittsburgh and Division Chief of Pulmonary Medicine at UPMC Children’s Hospital of Pittsburgh, PA, USA.
What are the advantages of an online congress and what do you miss compared with the classic on-site event?
The obvious advantage of the virtual format is that one can reach a larger international audience as it is easier for people from abroad to participate. Last I checked, we had about 47% of international registrants. The second advantage is the on-demand feature. If you are attending an in-person meeting, either you attend a session, or you don’t. In contrast, with most of the sessions available on demand until 2 July, people can watch whichever sessions they are interested in on their own schedule.
Of course, what the majority of participants look forward to the most, is the in-person interaction. We made a great effort to provide this possibility on the virtual format as much as we could (e.g, with question-and-answer sessions and possibilities for interactions with the speakers), but I would say it is not the same as an in-person meeting.
What have been the most interesting sessions at ATS 2021 for you?
My entire career has been on research in minority populations and so I was very pleased to see the number of sessions about issues related to disparities in respiratory diseases. When you look at the programme, there was a high number of sessions addressing racism, health disparities related to race or ethnicity, the role of gender and sex, and research in those fields. This was all quite interesting to me.
What do you think are/were the biggest challenges for clinicians during the pandemic?
I think that at the height of the pandemic, depending on where you were in the world, you dealt with a tremendously increased workload and in some settings with limited resources, whether in staffing, supplies, or treatment. I think it was devastating for many of our colleagues to lose patients to COVID-19 in an intensive care unit (ICU) without their family around or, if possible at all, only by zoom. Moreover, clinicians were socially isolated, which added to their toll, particularly for those working in ICUs. Besides, everybody but particularly women and younger people have had to deal with the closure of in-person attendance at schools and thus increased pressure at home, while also having to manage an increased clinical workload. For physician-scientists, all the pressures posed by the pandemic may have negatively impacted their time for research.
How do you reach your patients with chronic diseases in this difficult time?
I would be afraid to generalise, but some hospitals have switched to virtual consults relatively quickly. Even as conditions improved, patients were still reluctant to take in-person visits because of their fear of COVID-19. Thus, I think in many countries, regions, and cities, patients and physicians have tried to do telemedicine appointments. This has been necessary and has worked to some extent, particularly for routine and non-complex visits. However, many patients miss face-to-face contact with their physicians.
So, what is your opinion on virtual contact/telemedicine?
COVID-19 has been a great accelerator in clinical care and education, including the broader adoption of telemedicine. Early in the pandemic, the ATS co-led a series of webinars with our peer societies around the world, which had a very high attendance because clinicians wanted to have the latest information on the prevention, diagnosis, and management of COVID-19. Indeed, the virtual (webinar) format for education has been very valuable to clinicians worldwide during the pandemic. As noted above, telemedicine has gained its rightful place in patient care and consultation work, allowing discussion of cases with our colleagues around the globe.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« No increased risk of (severe) COVID-19 among IBD patients Next Article
Letter from the Editor »
« No increased risk of (severe) COVID-19 among IBD patients Next Article
Letter from the Editor »
Table of Contents: ATS 2021
Featured articles
Letter from the Editor
COVID-19: What Pulmonologists Need to Know
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
Asthma – An Update
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Sleep Disorders – An Underestimated Problem
OSA: A risk factor for earlier cognitive decline
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Association between positive airway pressure treatment adherence and COVID-19 infection rates
COPD – What Is New
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
Metabolic Dysregulation and Lung Disease
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Best of the Posters
Air pollution in winter linked to more hospital admissions in ILD patients
Tobacco biomarkers do not improve prediction of lung cancer risk
Vaping identified as risk factor for asthma
Related Articles
November 28, 2019
Registry confirms nintedanib efficacy under real-life conditions
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com